These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 24755179)

  • 1. [Round table 4. Speeding new therapeutic approaches for rare diseases: do we need new economical models or financial tools?].
    Med Sci (Paris); 2014 Apr; 30 Spe(1):47-53. PubMed ID: 24755179
    [No Abstract]   [Full Text] [Related]  

  • 2. [Going from research to development: which support and financing tools?].
    Roques S
    Presse Med; 2012 May; 41 Suppl 1():S43-5. PubMed ID: 22465719
    [No Abstract]   [Full Text] [Related]  

  • 3. Uncommon ventures launch to tackle uncommon diseases.
    Dolgin E
    Nat Med; 2013 Aug; 19(8):950-1. PubMed ID: 23921728
    [No Abstract]   [Full Text] [Related]  

  • 4. The European rare diseases therapeutic initiative.
    Fischer A; Borensztein P; Roussel C
    PLoS Med; 2005 Sep; 2(9):e243. PubMed ID: 16104832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Jumpstarting research into neglected diseases.
    Leslie M
    Cell; 2006 Nov; 127(3):443-5. PubMed ID: 17081963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Conference 1. An economic observatory for orphan drugs: myth or reality?].
    Duguet C; Ferry A
    Med Sci (Paris); 2014 Apr; 30 Spe(1):21-3. PubMed ID: 24755173
    [No Abstract]   [Full Text] [Related]  

  • 7. [The challenges of medicoeconomic assessment, benefit for the patient].
    Meyer F
    Presse Med; 2012 May; 41 Suppl 1():S29-31. PubMed ID: 22503292
    [No Abstract]   [Full Text] [Related]  

  • 8. [Round table 1. PNMR 2011-2014: point of view of the stakeholders].
    Med Sci (Paris); 2014 Apr; 30 Spe(1):8-13. PubMed ID: 24755171
    [No Abstract]   [Full Text] [Related]  

  • 9. Rare diseases mean big profits.
    Murphy RM
    Fortune; 2012 Sep; 166(4):24. PubMed ID: 23072062
    [No Abstract]   [Full Text] [Related]  

  • 10. [ERDITI, The European Rare Diseases Therapeutic Initiative: a public-private partnership is promoting research on new treatments for rare diseases].
    Gilgenkrantz S; Borensztein P
    Med Sci (Paris); 2006 Jan; 22(1):84-6. PubMed ID: 16386228
    [No Abstract]   [Full Text] [Related]  

  • 11. [Presenting a research project on rare diseases to industrial companies].
    Ferry A
    Presse Med; 2012 May; 41 Suppl 1():S38-9. PubMed ID: 22483767
    [No Abstract]   [Full Text] [Related]  

  • 12. Lucrative niches: how drugs for rare diseases became lifeline for companies.
    Anand G
    Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
    [No Abstract]   [Full Text] [Related]  

  • 13. [Workshops A1 to A5].
    Med Sci (Paris); 2014 Apr; 30 Spe(1):33-9. PubMed ID: 24755177
    [No Abstract]   [Full Text] [Related]  

  • 14. A new era of hope for the world's most neglected diseases.
    The
    PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Goodbye Columbus! New NRDOs forego discovery.
    Thiel KA
    Nat Biotechnol; 2004 Sep; 22(9):1087-92. PubMed ID: 15340473
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug patent plan gets mixed reviews.
    Butler D
    Nature; 2009 Feb; 457(7233):1064. PubMed ID: 19256077
    [No Abstract]   [Full Text] [Related]  

  • 17. Congress vouches for priority review of childhood disease.
    Palmer R
    Nat Med; 2012 Feb; 18(2):181. PubMed ID: 22310666
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression.
    Zaric GS
    Health Econ; 2008 Nov; 17(11):1277-94. PubMed ID: 18186544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Not Available].
    Med Sci (Paris); 2016 Apr; 32 Spec No 1():29-33. PubMed ID: 27137859
    [No Abstract]   [Full Text] [Related]  

  • 20. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
    John JE
    Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.